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burden for clinical budgets. The regional data analysis indicates that patient access
to EGFR-mutation testing is significantly related to the density of clinics and of
specialized physicians in respective federal states. CONCLUSIONS: Decentralized
organization and funding of health care and diagnostics have led to significant
regional disparities. Therefore, a detailed analysis of regional health care struc-
tures in oncology is necessary.
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OBJECTIVES: Current practice for suspected acute coronary syndrome (ACS) in-
volves troponin testing 10-12 hours after symptom onset to diagnose myocardial
infarction (MI). We aimed to estimate the diagnostic accuracy of early biomarkers
for MI to determine if an earlier, accurate decision was possible. METHODS: A
systematic review of all diagnostic cohort studies of patients presenting with sus-
pected ACS comparing the following biomarkers at presentation with a reference
standard based on the Universal definition of MI (troponin at 10-12 hours): early
troponin I and T; Heart-type Fatty Acid Binding Protein (HFABP); ischaemia modi-
fied albumen (IMA) and myoglobin. A systematic search was undertaken of 10
electronic databases, citation lists and expert contacts, to identify relevant studies.
The study selection, data extraction and quality assessment decisions were all
verified by more than one reviewer. citations retrieved were divided between two
reviewers (CC, SG) and screened for relevance to the review. Any discrepancies
were resolved by discussion and reference to the full paper. Risk of bias was as-
sessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)
tool. Meta-analysis was conducted using Bayesian Markov chain Monte Carlo
simulation. RESULTS: Compared with the Universal definition of MI, sensitivity
and specificity (95% predictive interval) were 77% (29-96%) and 93% (46-100%) for
troponin I; 80% (33-97%) and 91% (53-99%) for troponin T (99th percentile thresh-
old); 81% (50-95%) and 80% (26-98%) for quantitative HFABP, 68% (11-97%) and 92%
(20-100%) for qualitative HFABP; 77% (19-98%) and 39% (2-95%) for IMA and 62%
(35-83%) and 83% (35-98%) for myoglobin. CONCLUSIONS: Early troponin I and T
and H-FABP have modest sensitivity and specificity for MI at presentation, when
compared with the gold standard, but estimates are subject to substantial uncer-
tainty and primary data are subject to substantial heterogeneity. More research on
high sensitivity troponin assays at presentation is required.
PMD90
RENAL DENERVATION FOR RESISTANT HYPERTENSION: HTA REPORT OF THE
VENETO REGION
Lopatriello S1, Filippi C2, Bassotto F3, Redomi A1, Scroccaro G4
1UVEF-CTRDM, Verona, Italy, 2Azienda Ospedaliera Universitaria Integrata di Verona, Verona,
Italy, 3UVEF -CTRDM, Verona, Italy, 4Regione del Veneto, Venezia, Italy
OBJECTIVES: The regional Committee for Medical Devices Evaluation drafted the
HTA report for decision making on denervation of renal artery by catheter-based
radioablation in the treatment of resistant hypertension. METHODS: The report
was implemented in the respect of the INAHTA checklist form and its next versions
(WP4-EUnetHTA Project). Major literature and institutional databases were
searched (November 2011). A budget impact analysis (3-year horizon) in the re-
gional perspective was implemented on patients (aged 35-75) affected by resistant
hypertension (diastolic blood pressure 140mm/Hg) on politherapy treatment
(four antihypertensive drugs, including a diuretic). The target population excluded
secondary hypertension and included subjects actually hypertensive, treated, and
resistant to therapies, affected by comorbidities. The model was populated by
literature data as to epidemiology, resources consumption of denervation proce-
dure and cost/patient/year of antihypertensive therapy (visits, drugs, comorbidi-
ties management). Units costs were derived from a hospital accounting office (2010
values). RESULTS:No guidelines mentioned radiofrequency energy device as alter-
native to antihypertensives. Published clinical data, even limited, reveal an encour-
aging security profile. Two trials assessed blood pressure reduction in treated pa-
tients, at 2 years and 6 months. Seven clinical trial were found as on going. No
report of HTA or cost evaluation are published.The model target population con-
sisted of 8.559 subjects. Procedure costs, including overheads costs, was estimated
to be about €7,000; usual antihypertensive treatment about €600/patient/year. The
introduction of the device in clinical practice (hypothesis: 2% at 3rd year) would
increase regional expenditure in the range of 5%- 22%, respectively at 1st and 3rd
year from implementation. The model was sensitive to antihypertensives cost and
number of eligible patients. On the basis of clinical evidences, a one-year controlled
introduction of procedure was decided. CONCLUSIONS: Renal denervation is a
potential alternative in the treatment of patients affected by resistant hyperten-
sion.
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OBJECTIVES:A lot of uncertainties exist when introducing new technologies to the
health care market. The objective of this study is to construct different implemen-
tation scenarios of Home Brain Monitoring (HBM) in epilepsy patients and to value
these scenarios by making use of real options modeling to address uncertainty.
This model tries to show the (financial) consequences of different uncertainties on
the total value of the HBM project to facilitate investment decisions in the future.
METHODS: Individual semi-structured interviews were used to present (imple-
mentation) uncertainties to 19 epilepsy experts. Expert elicitation was used to
collect beliefs regarding uncertainties of HBM and to estimate probabilities of ‘suc-
cess’ of uncertainties. Scenarios were constructed, each of which describe a set of
uncertainties. These uncertainties were resolved in order to obtain a production
process with a certain expected value. Finally, a real options model was developed
that shows the influence of uncertainties on the total value of the HBM project.
Sensitivity analysis was used to demonstrate the impact of different uncertainties.
RESULTS: Elicited judgments show that a promising implementation scenario of
HBM in the diagnostic track of epilepsy could be the implementation of HBM after
a negative routine EEG, as a substitution of subsequent recordings and with the
support of a detection algorithm to detect events automatically. The probability of
success was lowest for implementing HBM without making use of a detection
algorithm. However, implementing HBM before the first EEG recording yields the
highest value, but it is not likely to happen.CONCLUSIONS: The implementation of
HBM after routine EEG seems to be preferred. The real options model provides an
innovative way to represent and value uncertainty in R&D projects. This model is
used for the first time in health care technology and provides a comprehensive, but
not-too-detailed view of challenges and key criteria for success.
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OBJECTIVES: A range of inhaler devices is available for the delivery of treatments
for respiratory diseases (pressurized metered-dose inhalers [pMDIs], non-refillable
and refillable dry-powder inhalers [DPIs], and breath-actuated metered-dose inhal-
ers [BA-MDIs]). Sales data from retail pharmacies in the five largest European coun-
tries for the period from Q4 2005 to Q4 2011 were analysed as a measure of inhaler
use in respiratory disease therapy. METHODS: Sales data were obtained from the
MIDAS database (IMS Health, London, UK) for CFC-free pMDIs, DPIs (non-refillable
and refillable) and BA-MDIs. Retail unit (RU) sales were analysed on a quarterly
basis, with one RU equating to one pack of inhalers. RESULTS: pMDIs accounted for
more than 50% of the total inhalers used across the four device types in every
quarter analysed. At the beginning of the study period, pMDIs accounted for 58.0%
of inhalers used, with non-refillable DPIs, refillable DPIs and BA-MDIs accounting
for 25.2%, 12.5% and 4.3%, respectively. At the end of the study period, the corre-
sponding percentages were 55.6% for pMDIs, 25.8% for non-refillable DPIs, 15.3% for
refillable DPIs and 3.3% for BA-MDIs. For each quarter, the number of pMDI RUs sold
was approximately twice that of non-refillable DPIs and three times that of refill-
able DPIs. The highest total number of RUs (45.7 million) was recorded in the most
recent quarter analysed; pMDIs accounted for 25.4 million RUs, compared with 11.8
million for non-refillable DPIs, 7.0 million for refillable DPIs and 1.48 million
BA-MDIs. CONCLUSIONS: These retail pharmacy data suggest that pMDIs are the
most commonly used inhaler for the treatment of respiratory disease in the five
largest EU countries. The trends observed in this analysis may reflect physician
consideration of factors such as the real-world effectiveness of, and the overall
health care costs associated with, the different inhaler types.
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OBJECTIVES: Early evaluations of new technologies require knowledge about cur-
rent care. Guidelines are sometimes used as a proxy. We examined the degree of
compliance to guidelines for the care of patients with a recent TIA or minor isch-
emic stroke. We specifically focussed on the guidelines for carotid stenosis imaging
and treatment criteria. METHODS: Semi-structured interviews are being con-
ducted with neurologists and radiologists in 13 hospitals in different regions in the
Netherlands. Questions were asked about the use of initial and confirmatory non-
invasive imaging tests to assess carotid stenosis (emergency and outpatient clinic),
criteria used to perform confirmatory tests and treatment criteria. We also exam-
ined the causes of variation and reasons for deviating from the guidelines.
RESULTS:To date, we have conducted interviews with specialists at nine hospitals.
The Dutch guidelines recommend duplex ultrasonography (DUS) as initial test. If
carotid stenosis is70% for females or 50-69% for males, a confirmatory computed
tomography angiography (CTA) or magnetic resonance angiography is advised. We
observed that only four of nine hospitals actually follow these guidelines in current
practice; the other hospitals use differing test combinations (e.g. CTA only with no
confirmatory test; or two DUS tests, followed by confirmatory CTA if DUS results
differ). According to clinicians, these differences are caused by varying expertise in
performing tests, capacity problems and preferences of vascular surgeons. We
observed little variation in treatment criteria, with good correspondence to the
guidelines. CONCLUSIONS: If guidelines are not followed, then early economic
evaluations using guidelines as the basis to describe current care may lead to
incorrect conclusions about the cost-effectiveness of a new technology. Moreover,
important practice variation means that the use of just one comparator is unjus-
tified. Assessments of health and economic impact of new imaging technology will
therefore be hospital-dependent and require multiple comparisons and scenarios.
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